The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2024-01-01 Epub Date: 2024-01-17 DOI:10.1159/000536060

Shun Iwai, Nozomu Motono, Tsunehiro Oyama, Akihiro Shioya, Sohsuke Yamada, Hidetaka Uramoto

{"title":"The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma.","authors":"Shun Iwai, Nozomu Motono, Tsunehiro Oyama, Akihiro Shioya, Sohsuke Yamada, Hidetaka Uramoto","doi":"10.1159/000536060","DOIUrl":null,"url":null,"abstract":"Purpose: We aimed to elucidate the functions and clinical relevance of sodium-glucose cotransporter 2 (SGLT2) in resected lung adenocarcinoma.Methods: The protein expression of SGLT2 in tumor samples from 199 patients with lung adenocarcinoma was analyzed by immunohistochemistry, and the protein expression, clinical variables, and survival outcomes were compared.Results: The median SGLT2 expression was significantly higher in advanced-stage and more aggressive adenocarcinomas. Age ≥70 (p < 0.01), BI ≥600 (p < 0.01), PRDX4 <25 (p < 0.01), and SGLT2 ≥12% (p = 0.03) were significant factors for RFS in multivariate analysis. Significant differences were observed in the RFS rates of the groups divided using the cutoff value of SGLT2 ≥12% (5-year RFS: 72.6% vs. 90%) (p < 0.01).Conclusion: The expression of SGLT2 was more frequently detected in advanced-stage and more aggressive adenocarcinomas with aggressive biological behavior than in their counterparts. The survival analysis revealed that the strong expression of SGLT2 was associated with poorer RFS. The SGLT2 expression predicts postoperative recurrence in lung adenocarcinoma patients.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"710-719"},"PeriodicalIF":2.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000536060","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We aimed to elucidate the functions and clinical relevance of sodium-glucose cotransporter 2 (SGLT2) in resected lung adenocarcinoma.

Methods: The protein expression of SGLT2 in tumor samples from 199 patients with lung adenocarcinoma was analyzed by immunohistochemistry, and the protein expression, clinical variables, and survival outcomes were compared.

Results: The median SGLT2 expression was significantly higher in advanced-stage and more aggressive adenocarcinomas. Age ≥70 (p < 0.01), BI ≥600 (p < 0.01), PRDX4 <25 (p < 0.01), and SGLT2 ≥12% (p = 0.03) were significant factors for RFS in multivariate analysis. Significant differences were observed in the RFS rates of the groups divided using the cutoff value of SGLT2 ≥12% (5-year RFS: 72.6% vs. 90%) (p < 0.01).

Conclusion: The expression of SGLT2 was more frequently detected in advanced-stage and more aggressive adenocarcinomas with aggressive biological behavior than in their counterparts. The survival analysis revealed that the strong expression of SGLT2 was associated with poorer RFS. The SGLT2 expression predicts postoperative recurrence in lung adenocarcinoma patients.

查看原文本刊更多论文

肺腺癌中 SGLT2 表达的临床意义。

目的：我们旨在阐明钠-葡萄糖共转运体2（SGLT2）在切除的肺腺癌中的功能和临床意义：方法：采用免疫组化方法分析199例肺腺癌患者肿瘤样本中SGLT2的蛋白表达，并比较蛋白表达、临床变量和生存结果：结果：在晚期和侵袭性更强的腺癌中，SGLT2的中位表达量明显更高。在多变量分析中，年龄≥70（P＜0.01）、BI≥600（P＜0.01）、PRDX4＜25（P＜0.01）和SGLT2≥12%（P=0.03）是影响RFS的重要因素。根据 SGLT2≥12% 的临界值划分的各组的 RFS 率存在显著差异（5 年 RFS：72.6% 对 90%）（PConclusion：在晚期、侵袭性更强且具有侵袭性生物学行为的腺癌中，SGLT2的表达比同类腺癌更频繁。生存分析表明，SGLT2 的强表达与较差的 RFS 相关。SGLT2的表达可预测肺腺癌患者的术后复发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.